BCTX
Briacell Therapeutics Corp
$
0.744
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.7566
Open
0.725
VWAP
0.74
Vol
633.04K
Mkt Cap
19.02M
Low
0.710
Amount
466.05K
EV/EBITDA(TTM)
--
Total Shares
18.28M
EV
-114.96K
EV/OCF(TTM)
--
P/S(TTM)
--
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Show More
1 Analyst Rating
4199.73% Upside
Wall Street analysts forecast BCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCTX is 31.99 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
4199.73% Upside
Current: 0.744
Low
32.00
Averages
31.99
High
32.00
4199.73% Upside
Current: 0.744
Low
32.00
Averages
31.99
High
32.00
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$32
2025-04-22
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$32
2025-04-22
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$15 → $32
2025-02-03
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15 → $32
2025-02-03
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2024-12-12
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2024-12-12
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2024-12-03
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2024-12-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2024-10-03
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2024-10-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$18 → $15
2024-09-19
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$18 → $15
2024-09-19
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Briacell Therapeutics Corp (BCTX.O) is -0.96, compared to its 5-year average forward P/E of -3.35. For a more detailed relative valuation and DCF analysis to assess Briacell Therapeutics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.35
Current PE
-0.96
Overvalued PE
-0.48
Undervalued PE
-6.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q3
YoY :
-31.44%
-6.33M
Operating Profit
FY2025Q3
YoY :
-467.85%
-6.22M
Net Income after Tax
FY2025Q3
YoY :
-201.86%
-1.64
EPS - Diluted
FY2025Q3
YoY :
+40.89%
-7.16M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BCTX News & Events
Events Timeline
2025-07-31 (ET)
2025-07-31
07:42:24
BriaCell adds UCLA Health as site in Phase 3 breast cancer study
2025-07-30 (ET)
2025-07-30
07:35:45
BriaCell awarded New Zealand patent for its whole cell technology
2025-07-29 (ET)
2025-07-29
07:39:55
BriaCell subsidiary BriaPro files patent application for TILsRx
Sign Up For More Events
Sign Up For More Events
News
9.0
07-31NewsfilterBriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
3.5
07-30NewsfilterBriaCell Awarded New Zealand Patent for its Whole Cell Technology
9.0
07-29NewsfilterBriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
Sign Up For More News
People Also Watch
CGAU
Centerra Gold Inc
6.940
USD
+2.06%
BKT
Blackrock Income Trust Inc
11.710
USD
+0.52%
BWLP
BW LPG Ltd
13.250
USD
-0.82%
BTG
B2Gold Corp
3.440
USD
+2.08%
BUR
Burford Capital Ltd
12.430
USD
-3.27%
CGABL
The Carlyle Group Inc. 4.625% Subordinated Notes Due 2061
18.000
USD
-0.72%
BHFAL
Brighthouse Financial Inc
18.550
USD
+0.05%
CGC
Canopy Growth Corp
1.050
USD
+1.94%
BEP
Brookfield Renewable Partners LP
25.830
USD
-6.24%
CGBDL
Carlyle Secured Lending Inc
26.069
USD
+1.04%
FAQ
What is Briacell Therapeutics Corp (BCTX) stock price today?
The current price of BCTX is 0.744 USD — it has decreased -0.27 % in the last trading day.
What is Briacell Therapeutics Corp (BCTX)'s business?
What is the price predicton of BCTX Stock?
What is Briacell Therapeutics Corp (BCTX)'s revenue for the last quarter?
What is Briacell Therapeutics Corp (BCTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Briacell Therapeutics Corp (BCTX)'s fundamentals?
How many employees does Briacell Therapeutics Corp (BCTX). have?